Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: Results of a 1-year, phase IIa, single-arm, open-label clinical trial Academic Article uri icon

Overview

MeSH Major

  • Dermatologic Agents
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Scleroderma, Diffuse

abstract

  • Treatment with imatinib was tolerated by most patients in this cohort. Although AE were common, most were mild to moderate. In this open-label experience, improvements in skin thickening and FVC were observed. Further investigation of tyrosine kinase inhibition for dcSSc in a double-blind randomised placebo controlled trial is warranted. ClinicalTrials.gov, NCT00555581.

publication date

  • June 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3086082

Digital Object Identifier (DOI)

  • 10.1136/ard.2010.143974

PubMed ID

  • 21398330

Additional Document Info

start page

  • 1003

end page

  • 9

volume

  • 70

number

  • 6